Author

Didier Raoult

IHU M

Biography

Didier Raoult, M.D., Ph.D. is a graduate of Marseille Medical School and performed internal medicien and infectious disease specialty training there also. He received degrees in bacteriology and virology (1981) and parasitology (1982). He obtained his Ph.D. in microbiology at Montpellier, France, in 1985. He is full Professor at Marseille School of Medicine and is Director of the Clinical Microbiology Laboratory for the University Hospitals. He is President of the Universite de la Mediterranee in Marseille. He is the co-founder of the European Study Group of Rickettsia, Ehrlichia, Coxiella (EUWOG) for which he is the immediate past president. 
Title
Cited by
Year
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
P Gautret, JC Lagier, P Parola, L Meddeb, M Mailhe, B Doudier, J Courjon, ...International journal of antimicrobial agents 56 (1), 105949, 2020202
6179
2020
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
CA Devaux, JM Rolain, P Colson, D RaoultInternational journal of antimicrobial agents 55 (5), 105938, 2020202
1284
2020
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
P Colson, JM Rolain, JC Lagier, P Brouqui, D RaoultInternational journal of antimicrobial agents 55 (4), 105932, 2020202
1131
2020
Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards
B La Scola, M Le Bideau, J Andreani, VT Hoang, C Grimaldier, P Colson, ...European Journal of Clinical Microbiology & Infectious Diseases 39 (6), 1059 …, 2020202
897
2020
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
P Gautret, JC Lagier, P Parola, L Meddeb, J Sevestre, M Mailhe, ...Travel medicine and infectious disease 34, 101663, 2020202
887
2020
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France
M Million, JC Lagier, P Gautret, P Colson, PE Fournier, S Amrane, ...Travel medicine and infectious disease 35, 101738, 2020202
549
2020
Chloroquine for the 2019 novel coronavirus SARS-CoV-2
P Colson, JM Rolain, D RaoultInternational journal of antimicrobial agents 55 (3), 105923, 2020202
545
2020
ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome
CA Devaux, JM Rolain, D RaoultJournal of Microbiology, Immunology and Infection 53 (3), 425-435, 2020202
495
2020
Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses
D Raoult, A Zumla, F Locatelli, G Ippolito, G KroemerCell stress 4 (4), 66, 2020202
386
2020
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
J Andreani, M Le Bideau, I Duflot, P Jardot, C Rolland, M Boxberger, ...Microbial pathogenesis 145, 104228, 2020202
329
2020
Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?
SA Baron, C Devaux, P Colson, D Raoult, JM RolainInternational journal of antimicrobial agents, 105944, 2020202
308
2020
Antibiotic discovery: history, methods and perspectives
GA Durand, D Raoult, G DubourgInternational journal of antimicrobial agents 53 (4), 371-382, 2019201
308
2019
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
JC Lagier, M Million, P Gautret, P Colson, S Cortaredona, ...Travel medicine and infectious disease 36, 101791, 2020202
282
2020
Correlation between 3790 quantitative polymerase chain reaction–positives samples and positive cell cultures, including 1941 severe acute respiratory syndrome coronavirus 2 …
R Jaafar, S Aherfi, N Wurtz, C Grimaldier, T Van Hoang, P Colson, ...Clinical Infectious Diseases 72 (11), e921-e921, 2021202
196
2021
Bacterial culture through selective and non-selective conditions: the evolution of culture media in clinical microbiology
M Bonnet, JC Lagier, D Raoult, S KhelaifiaNew microbes and new infections 34, 100622, 2020202
196
2020
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
A Fluckiger, R Daillere, M Sassi, BS Sixt, P Liu, F Loos, C Richard, ...Science 369 (6506), 936-942, 2020202
184
2020
Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients
L Derosa, B Routy, M Fidelle, V Iebba, L Alla, E Pasolli, N Segata, ...European urology 78 (2), 195-206, 2020202
172
2020
Evaluation of the Panbio Covid-19 rapid antigen detection test device for the screening of patients with Covid-19
F Fenollar, A Bouam, M Ballouche, L Fuster, E Prudent, P Colson, ...Journal of clinical microbiology 59 (2), 10.1128/jcm. 02589-20, 2021202
168
2021
Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France,-January 31st to March …
S Amrane, H Tissot-Dupont, B Doudier, C Eldin, M Hocquart, M Mailhe, ...Travel medicine and infectious disease 36, 101632, 2020202
132
2020
Immune responses during COVID-19 infection
C Melenotte, A Silvin, AG Goubet, I Lahmar, A Dubuisson, A Zumla, ...Oncoimmunology 9 (1), 1807836, 2020202
125
2020

Referred From: https://scholar.google.com/citations?hl=en&user=n8EF_6kAAAAJ

Cited by
Citations 218058
h-index 206
i10-index 2057
Recommended Journals
Open Access Journals